5 assets in Pheochromocytoma-Paraganglioma

Therapeutic assets addressing Pheochromocytoma-Paraganglioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P1/2	CCC (54)
FAPI74 Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P2	CCC (53)
Fludeoxyglucose Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Pheochromocytoma-Paraganglioma	Fundación de investigación HM	P1/2	CCC (48)
[212pb]vmt-alpha-net Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P1	CC (43)